Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Trifluridine/Tipiracil + Bevacizumab in Refractory Metastatic Colorectal Cancer
NCT07085169Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil in colorectal cancer (CRC), sponsored by Ruijin Hospital. Started Aug 2025; status: recruiting.
02
Drugs
trifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07085169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07085169.